Sign up for the QMED & MD+DI Daily newsletter.
January 8, 2024
2 Min Read
Yevhen Lahunov / iStock / Getty Images Plus via Getty Images
GE HealthCare today announced it has entered into an agreement to acquire MIM Software, a company offering medical imaging analysis and artificial intelligence solutions.
MIM’s software is used in radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations. The company’s portfolio provides multiple features, including the integration of diagnostic images from multiple modalities into treatment plans, automation to help reduce repetitive tasks and manual interventions, quantitation and advanced processing in diagnostic imaging and nuclear medicine to determine therapy choice, and a platform to assist with Theranostics imaging and dosimetry.
“We are excited by the prospect of joining GE HealthCare and thrilled to share this exciting news,” said Andrew Nelson, CEO of MIM, in the press release announcing the agreement. “Over the past two decades, we have worked to develop innovative vendor agnostic products and deliver quality services to earn the trust of our customers — this will not change. As a part of GE HealthCare, we anticipate developing new and increasingly integrated digital solutions to meet our customers’ most complex and pressing needs, today and into the future. Together, we will build upon our shared legacies of enhancing patient care.”
GE said it intends to leverage the company’s imagining analytics and digital workflow capabilities across various care areas to “accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world,” according to the release.
This is expected to include the integration of MIM’s portfolio to facilitate dosimetry analysis for patients throughout treatment and in fields such as radiology, molecular imaging, and radiation oncology.
Additionally, GE said the integration will “facilitate AI-based segmentation and contouring,” according to the release.
“Our anticipated acquisition of MIM Software will mark a key moment in the evolution of our technology,” said Taha Kass-Hout, MD, MS, chief technology officer at GE. “By integrating MIM Software’s cutting-edge imaging analytics and AI-driven solutions with GE HealthCare’s advanced medical technology, we are not just expanding our capabilities, but joining together to embrace the possibilities of precision care. This intended merger is a fusion of innovative visions, aimed at evolving the way we detect, treat, and manage disease. GE HealthCare is committed to developing smart, AI-powered devices that cater to specific disease states, thereby enabling clinicians to deliver more personalized care. We expect the integration of MIM Software will also advance our efforts in connecting data across care pathways. It is a leap towards a future where healthcare is more precise, connected, and efficient, with the goal of benefitting providers and patients worldwide.”
MIM is currently headquartered in Cleveland, OH, with additional offices in China and Belgium. The financial details of the acquisition transaction have not, at the time of article publication, been publicly disclosed. GE said it intends to fund the acquisition using cash on hand. No timeline has been announced for when the deal will be closed.
About the Author(s)
Managing Editor, MD+DI
Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].
You May Also Like
Sustainable Manufacturing Expo Hits North AmericaFeb 22, 2024|4 Min Read
Medtronic Doubles Down on Sustainability EffortsFeb 22, 2024|1 Min Read
Top Medical Device M&AFeb 21, 2024|1 Min Read
FDA Urges Independent Verification of Third-Party Testing DataFeb 21, 2024|2 Min Read